Innovation Delivered: Resco Launches Autumn Update at resco.next 2019 Keynote
24.10.2019 17:47:00 EEST | Business Wire | Press release
Resco, the leading provider of enterprise mobility solutions for Microsoft Dynamics 365 and Salesforce, has today officially introduced the Autumn Update 2019 at its annual resco.next conference in Rome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191024005635/en/
Innovation delivered - Resco (Photo: Business Wire)
The release stands among Resco’s most significant, as it marks a year since the company officially began the expansion of its product portfolio with Resco Inspections, followed by Resco Routes. It delivers major new capabilities to both, as well as to the company’s Mobile Business Apps Platform.
“Our Autumn Update further strengthens Resco’s commitment to innovation that fosters business productivity. It also brings a number of features that extend Resco products to smartwatches,” confirmed Miro Pomsar, CEO at Resco.
More details in a fraction of time
With new Resco Inspections features like Tagged image and Reusable answers, field teams can complete inspections faster and provide more details with context to the back office. Ultimately, helping to speed up any issue resolution and boosting client satisfaction and loyalty.
Importantly, the solution is also coming to smartwatches as part of the Autumn Update. Field professionals can now complete inspection forms from their wrist, utilizing voice control for an entirely hands-free experience.
More information on Resco Inspections Autumn Update 2019 available here.
Handling unexpected situations
The upgraded Location Monitor in Resco Routes enables users to take the guesswork out of planning and effectively manage unforeseen events. Details such as an unlimited number of tracked staff members, real-time travel direction & speed, time of the last stop, and progress through the day, provide the backbone for truly informed decisions.
More information on Resco Routes Autumn Update 2019 available here.
Let the AI do the work
Resco’s Mobile Business Apps Platform has been extended with functionality that improves the efficiency of both mobile users and system administrators.
The all-new AI image recognition is available across all Resco-based app. Mobile users can now utilize image recognition instead of search or barcode scanning. More complex scenarios are also possible when utilizing image recognition in form rules.
Furthermore, when using Resco Cloud as a backend, administrators can create new fields and entities on the system directly from Woodford – no need to switch between applications. And with new project item categories, they can bring structure and clarity even to complex mobile projects.
More information on Resco’s Mobile Business Apps Platform Autumn Update 2019 available here.
Industry Watch for deeper business insights
At resco.next the company also introduced its all-new Industry Watch initiative - a new concept of utilizing smartwatches to obtain more insights from staff outdoors and indoors. Making entire organizations smarter and more efficient.
“We are excited about this new venture and the road that lies ahead. In the following months, we’re going to continue our intensive research in the area of wearables. We would also like to engage our whole ecosystem into this initiative, including our partners.” Miro Pomsar explained.
More details regarding Resco’s new smartwatch initiative can be found here.
About Resco
Resco founded in 1999, is one of the global leaders in developing cross-platform mobile software solutions. The team of Resco professionals utilizes their knowledge to design products for corporate customers, developers, integrators, and end users. Today, Resco is utilized by 2,800+ corporate customers with more than 250,000 licensed users around the world. The cornerstone of Resco’s Mobile Business Apps Platform is the Woodford configuration and management tool, which together with the Resco mobile app form the base of all Resco products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005635/en/
Contact information
Resco Media Relations
Robert Feldmar
+421 2 209 020 17
communications@resco.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom